170 related articles for article (PubMed ID: 38506226)
1. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract][Full Text] [Related]
2. Metabolic parameters predict survival and toxicity in chimeric antigen receptor T-cell therapy-treated relapsed/refractory large B-cell lymphoma.
Ababneh HS; Ng AK; Abramson JS; Soumerai JD; Takvorian RW; Frigault MJ; Patel CG
Hematol Oncol; 2024 Jan; 42(1):e3231. PubMed ID: 37795759
[TBL] [Abstract][Full Text] [Related]
3. Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy.
Hubbeling H; Silverman EA; Michaud L; Tomas AA; Shouval R; Flynn J; Devlin S; Wijetunga NA; Tringale KR; Batlevi C; Dahi P; Giralt S; Lin R; Park J; Scordo M; Sauter C; Shah G; Hajj C; Salles G; Schoder H; Palomba ML; Perales MA; Yahalom J; Imber BS
Transplant Cell Ther; 2023 Apr; 29(4):259.e1-259.e10. PubMed ID: 36587744
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
5. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of peripheral eosinophil counts in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy.
Dang X; Ye S; Zhou L; Lu Y; Li P; Liang A; Qian W
Cytotherapy; 2023 Jun; 25(6):573-577. PubMed ID: 36456447
[TBL] [Abstract][Full Text] [Related]
8. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
10. [
Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
[TBL] [Abstract][Full Text] [Related]
11. [
Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
Eur J Nucl Med Mol Imaging; 2024 Mar; ():. PubMed ID: 38467921
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
13. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Beyar Katz O; Perry C; Grisariu-Greenzaid S; Yehudai-Ofir D; Luttwak E; Avni B; Zuckerman T; Sdayoor I; Stepensky P; Ringelstein-Harlev S; Bar-On Y; Libster D; Sharvit L; Amit O; Greenbaum U; Gold R; Herishanu Y; Benyamini N; Avivi I; Ram R
Eur J Haematol; 2023 Jul; 111(1):63-71. PubMed ID: 36964939
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient.
Hu L; Wu F; Wang H; Zhu W; Wang J; Yu F; Zhai Z
Front Immunol; 2021; 12():665230. PubMed ID: 33953727
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
16. Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
Del Toro-Mijares R; Oluwole O; Jayani RV; Kassim AA; Savani BN; Dholaria B
Br J Haematol; 2023 Apr; 201(1):15-24. PubMed ID: 36709623
[TBL] [Abstract][Full Text] [Related]
17. Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Voltin CA; Paccagnella A; Winkelmann M; Heger JM; Casadei B; Beckmann L; Herrmann K; Dekorsy FJ; Kutsch N; Borchmann P; Fanti S; Kunz WG; Subklewe M; Kobe C; Zinzani PL; Stelljes M; Roth KS; Drzezga A; Noppeney R; Rahbar K; Reinhardt HC; von Tresckow B; Seifert R; Albring JC; Blumenberg V; Farolfi A; Flossdorf S; Gödel P; Hanoun C
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1361-1370. PubMed ID: 38114616
[TBL] [Abstract][Full Text] [Related]
18. [Roles of PET/CT in Predicting the Prognosis of Diffuse Large B Cell Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy].
Zheng XQ; Ding CY; Zou YX; Zhu HY; Wang L; Fan L; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1189-1196. PubMed ID: 32798397
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma.
Mirza AS; Kumar A; Hashmi H; Garcia F; Logothetis CN; Darwin A; Faramand R; Reid K; Bachmeier C; Chavez JC; Shah B; Pinilla-Ibarz J; Khimani F; Lazaryan A; Liu H; Davila ML; Nishihori T; Locke FL; Jain MD
Transplant Cell Ther; 2021 Mar; 27(3):242.e1-242.e6. PubMed ID: 33781520
[TBL] [Abstract][Full Text] [Related]
20. Development of a radiomic-clinical nomogram for prediction of survival in patients with diffuse large B-cell lymphoma treated with chimeric antigen receptor T cells.
Zhou Y; Zhang B; Han J; Dai N; Jia T; Huang H; Deng S; Sang S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11549-11560. PubMed ID: 37395846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
